MedTrace Logo

Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19

NCT04452604 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 79

Last updated 2022-07-27

No results posted yet for this study

Summary

The COVID-19 epidemic (Coronavirus Disease 2019) currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). Epidemiologically, acute myeloblastic leukemias (AML) are the most common of acute leukemias. The incidence of acute lymphoblastic leukemia (ALL) is 900 new cases in France in 2018, of which 57% in humans. The treatments administered to AML and ALL patients induce variable immunosuppression: neutropenia, neuropathy, deficits in humoral or cellular immunity or combinations of these deficits. Patients with AML or ALL therefore represent a population at high risk of developing a serious form in the event of infection with SARS-CoV-2. To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in the population of patients with acute leukemia.

The main objective of the study is to determine the clinical and biological prognostic factors during SARS-CoV-2 infection in patients with acute leukemia.

Conditions

Sponsors & Collaborators

  • Acute Leukemia French Association

    collaborator OTHER

  • Group for Research in Adult Acute Lymphoblastic Leukemia

    collaborator OTHER

  • French Innovative Leukemia Organisation

    lead OTHER

Principal Investigators

  • Pierre-Yves DUMAS, Dr · French Innovative Leukemia Organisation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-11
Primary Completion
2021-06-30
Completion
2021-07-07

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04452604 on ClinicalTrials.gov